688217 Shanghai Rightongene Biotechnology
- 22.15
- -0.36-1.60%
Shanghai Rightongene Biotechnology News
Ruiang Gene (688217.SH): BCR-ABL P210 Fusion Gene Detection Kit has obtained the registration certificate for medical instruments.
On June 5th, Gelonhui reported that Ruian Gene (688217.SH) announced that its wholly-owned subsidiary, Suzhou Yuntai Biomedical Technology Co., Ltd., obtained the "Medical Device Registration Certificate (In Vitro Diagnostic Reagent)" issued by the National Medical Products Administration for its BCR-ABL P210 Fusion Gene Detection Test Kit (Fluorescent RT-PCR Method) recently. The approval of the Medical Device Registration Certificate for the BCR-ABL P210 fusion gene detection test kit (fluorescent RT-PCR method) is another important breakthrough for Ruian Gene in the field of leukemia detection.
Express News | Ruian Genetics: A wholly-owned subsidiary's product has obtained a medical instrument registration certificate.
Ruiong Gene (688217.SH): Shareholder Zhejiang Health plans to reduce its shareholding by no more than 2%.
On ****, Gelunhui reported that Ruiang Gene (688217.SH), due to the shareholder's own capital needs, Zhejiang Dahua intended to reduce its total shareholding by no more than 1,117,116 shares, accounting for no more than 2% of the company's total share capital, through centralized bidding and bulk trading. The shareholder, Zhejiang Dahua, intends to reduce the number of shares held by the company by no more than 558,558 shares, or no more than 1% of the total share capital of the company, through centralized bidding and not exceeding 1% of the total number of company shares issued and traded within any consecutive 90 natural days; intends to reduce the shares through bulk trading.
Genetron Holdings Limited (688217.SH): has cumulatively repurchased 1.20% of the company's shares.
As of May 31, 2024, Retechgene (688217.SH) announced that it has cumulatively repurchased 669,621 shares of the company through the Shanghai Stock Exchange trading system using centralized bidding trading, accounting for 1.20% of the total share capital of 55,855,896 shares. The highest and lowest prices for repurchase transactions were 27.67 yuan/share and 22.37 yuan/share respectively. The total amount paid was RMB 17,021,747.99 (excluding transaction fees such as stamp duty and brokerage commission).
Express News | Rayon Gene: Received a total of RMB 1.05 million in government grants
Express News | The ban on restricted shares with a market capitalization of 10.975 billion yuan was lifted today
About 18.351,400 restricted shares of Rayon Gene (688217.SH) will be listed and distributed from May 17
Rayon Gene (688217.SH) announced that the restricted shares listed and circulated are restricted shares of the company's initial public offering. The limited sale period is 36 months from the date of listing of the company's shares, involving 6 shareholders. The number of restricted shares corresponding to this group of shareholders is approximately 18.3514 million shares, accounting for 32.85% of the company's total share capital. Currently, the sales restriction period for the restricted shares mentioned above is about to expire, and they will be listed and circulated on May 17, 2024.
Rayon Gene (688217.SH): 1.20% of shares have been repurchased cumulatively
Gelonghui, May 7 | Ruiang Gene (688217.SH) announced that as of April 30, 2024, the company had repurchased 669,621 shares of the company through centralized bidding transactions, accounting for 1.20% of the company's total share capital of 55,855,896 shares. The highest price of the repurchase transaction was 27.67 yuan/share, the lowest price was 22.37 yuan/share, and the total amount of capital paid was RMB 17,021,747.99 (excluding transaction fees such as stamp duty and transaction fees).
Rayon Gene (688217.SH): Net profit for the first quarter was 533,200 yuan, down 58.70% year on year
On April 26, Ge Longhui (688217.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 64,1882 million yuan, a year-on-year increase of 12.84%; net profit attributable to shareholders of listed companies was 533,200 yuan, a year-on-year decrease of 58.70%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses - 614,600 yuan; and basic earnings per share.
Rayon Gene (688217): Oncology related core business is growing steadily, deepening applications in the field of accurate tumor diagnosis
Incident: Recently, the company released its 2023 annual report, and revenue declined. In 2023, the company achieved a total revenue of 258 million yuan, a year-on-year decrease of 39.14%; realized net profit to mother of 7.9307 million yuan, the same
Rayon Gene (688217.SH): Net profit of 7.93 million yuan in 2023 fell 80.41% year on year
On April 16, GLONGHUI (688217.SH) released its 2023 annual report, with operating income of 258 million yuan, a year-on-year decrease of 39.14%, net profit of 7.93 million yuan, a year-on-year decrease of 80.41%, after deducting non-net profit of 3.695 million yuan, a year-on-year decrease of 89%, with basic earnings of 0.14 yuan per share.
Rayon Gene (688217.SH) has bought back a total of 1.04% of its shares at a cost of 149.12,400 yuan
Rayon Gene (688217.SH) issued an announcement. As of March 29, 2024, the company approved Shanghai Securities...
Rayon Gene (688217.SH): A total of 120,000 shares have been repurchased as of February 29
Gelonghui, March 1, 丨 Ruiang Gene (688217.SH) announced that as of February 29, 2024, the company had repurchased 120,000 shares of the company's shares through centralized bidding transactions, accounting for 0.21% of the company's total share capital of 55,855,896 shares. The highest price of the repurchase transaction was 27.10 yuan/share, the lowest price was 25.02 yuan/share, and the total amount of capital paid was RMB 3,117,108.46 (excluding transaction fees such as stamp duty and transaction fees).
Rayon Gene (688217.SH): 0.11% share repurchase for the first time
Gelonghui, Feb. 28 | Ruiang Gene (688217.SH) announced that on February 28, 2024, the company repurchased 60,000 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.11% of the company's total share capital of 55,855,896 shares. The highest price of the repurchase transaction was 27.10 yuan/share, the lowest price was 25.26 yuan/share, and the total amount of capital paid was RMB 1,570,103.82.
Rayon Genomics (688217.SH): 2023 net profit fell 79.93% year on year
Gelonghui, Feb. 23 | Ruiang Gene (688217.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating revenue of 256.5730 million yuan, a decrease of 39.53% compared with the same period last year; realized operating profit - 7.244,400 yuan, down 110.10% from the same period last year; realized total profit - 9.9852 million yuan, down 113.84% from the same period last year; realized net profit attributable to the owner of the parent company, a decrease of 79.93% compared with the same period last year; achieved ownership to the parent Company owners' deductions are not infrequent
Express News | Rayon Gene: It is intended to repurchase shares for 15 million yuan to 20 million yuan, and the repurchase price will not exceed RMB 49 per share.
Rayon Gene (688217.SH): Currently no genetically engineered drugs have been developed
Gelonghui, December 29丨Ruiang Gene (688217.SH) said on the investor interactive platform that the company and the Chongqing Big Data Research Institute of Peking University have jointly built a “Joint Laboratory for Genetic Intelligence and Big Data”, focusing on diseases such as hematological systems, solid tumors, and geriatric diseases. At the 2023 China International Intelligent Industry Expo, the company and Peking University Chongqing Big Data Research Institute announced the results of cooperation between the two parties — a genetic big data intelligent computing platform. The platform is dedicated to an overall solution for managing the entire life cycle of genetic data from generation, storage, integration, calculation, analysis to application, and can be aimed at medical research
Rayon Gene (688217.SH): Currently, the company's main business is R&D, production and sales of in vitro diagnostic reagents
Gelonghui, December 28 | Ruiang Gene (688217.SH) said on the investor interactive platform that currently the company's main business is R&D, production and sales of in vitro diagnostic reagents. There are currently no R&D plans for synthetic proteins. The biotechnology reserve mainly means that the company has a reserve of protein-related biotechnology research and development personnel.
Rayon Gene (688217.SH): not involved in vaccine development
Glonghui, December 28 | Ruion Gene (688217.SH) said on the investor interactive platform that the company is mainly engaged in the field of in vitro diagnosis and does not involve vaccine research and development.
Rayon Gene (688217.SH): Currently, there are no genetic engineering techniques such as genetic recombination or gene editing
Gelonghui, December 28 | Ruian Gene (688217.SH) said on the investor interactive platform that the company currently has no genetic engineering technology such as genetic recombination or gene editing.
Analysis
Price Target
No Data
